caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.
![Lisata Therapeutics logo](/files/LOGO/320017-LSTA.png)
Company profile
Ticker
LSTA
Exchange
Website
CEO
David Mazzo
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., CORNICHE GROUP INC /DE, NeoStem, Inc., PHASE III MEDICAL INC/DE
SEC CIK
Corporate docs
Subsidiaries
Athelos Corporation • Lisata Therapeutics Australia Pty Ltd • Lisata Therapeutics Ireland Limited • Lisata Therapeutics (U.K.) Limited • As of December 31, 2023, Becton Dickinson's ownership interest in Athelos Corporation ...
IRS number
222343568
LSTA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
15 Jul 24
8-K
Results of Operations and Financial Condition
27 Jun 24
EFFECT
Notice of effectiveness
10 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
9 May 24
S-3
Shelf registration
1 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Departure of Directors or Certain Officers
17 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
Transcripts
LSTA
Earnings call transcript
2024 Q1
9 May 24
LSTA
Earnings call transcript
2023 Q3
2 Nov 23
LSTA
Earnings call transcript
2023 Q2
15 Aug 23
LSTA
Earnings call transcript
2023 Q2
15 Aug 23
LSTA
Earnings call transcript
2023 Q1
9 May 23
LSTA
Earnings call transcript
2022 Q4
30 Mar 23
LSTA
Earnings call transcript
2022 Q3
13 Nov 22
LSTA
Earnings call transcript
2022 Q2
5 Aug 22
LSTA
Earnings call transcript
2022 Q2
4 Aug 22
LSTA
Earnings call transcript
2022 Q1
6 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.81 mm | 21.81 mm | 21.81 mm | 21.81 mm | 21.81 mm | 21.81 mm |
Cash burn (monthly) | 262.67 k | 529.17 k | 2.20 mm | 2.12 mm | 2.34 mm | 1.57 mm |
Cash used (since last report) | 1.02 mm | 2.05 mm | 8.51 mm | 8.20 mm | 9.06 mm | 6.08 mm |
Cash remaining | 20.79 mm | 19.76 mm | 13.30 mm | 13.60 mm | 12.75 mm | 15.73 mm |
Runway (months of cash) | 79.1 | 37.3 | 6.0 | 6.4 | 5.4 | 10.0 |
Institutional ownership, Q1 2024
33.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 891.42 mm |
Total shares | 2.81 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 1.58 mm | $0.00 |
Intracoastal Capital | 949.61 k | $2.21 mm |
BML Capital Management | 284.67 k | $888.17 mm |
Founders Capital Management | 333.00 | $1.04 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jan 24 | David J Mazzo | Common Stock | Payment of exercise | Dispose F | No | No | 2.99 | 1,026 | 3.07 k | 174,766 |
9 Jan 24 | Azab Mohammad | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 58,680 |
9 Jan 24 | Brown Gregory B | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 49,414 |
9 Jan 24 | Schwalm Cynthia | Common Stock | Grant | Acquire A | No | No | 0 | 19,480 | 0.00 | 49,201 |
News
Quest Diagnostics' Haystack Oncology Forges New MRD Deal
24 Jul 24
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
19 Jul 24
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
18 Jul 24
Lisata Stock Rallies More Than 30% YTD: Here's Why
16 Jul 24
Lisata Therapeutics Completes Enrollment In Its Phase 2a BOLSTER Trial Of Certepetide In First-Line Cholangiocarcinoma
16 Jul 24
Press releases
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
18 Jul 24
Lisata Therapeutics CEO encouraged by progress on pancreatic cancer trial
14 Jun 24
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
28 May 24
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
20 May 24
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
13 May 24